drugset
drugset / Trial / NCT00890656

Study of Augmented Hyper-CVAD in Acute Lymphoblastic Leukemia Salvage

NCT00890656 ↗

Phase 2 Completed 90 enrolled M.D. Anderson Cancer Center Enzon Pharmaceuticals, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if a special combination of chemotherapy drugs called "augmented hyper-CVAD chemotherapy" given over 6 to 8 months followed by monthly maintenance chemotherapy for one year can help to control acute lymphoblastic leukemia or lymphoblastic lymphoma. The safety of this therapy will also be studied.

Timeline

Start
2003-06
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 300 mg/m2 Intravenous
Subject Cytarabine Small molecule 3 g Intravenous
Subject Dexamethasone Small molecule 80 mg Intravenous
Subject Doxorubicin Other / unclassified 50 mg/m2 Intravenous
Subject Methotrexate Small molecule 800 mg/m2 Intravenous
Subject Pegaspargase Protein / enzyme biologic 2500 unknown Intravenous
Subject Vincristine Small molecule 2 mg Intravenous
Background G-CSF Unknown 10 ug/kg Intravenous

Indications

acute lymphoblastic leukemia